Pfizer Ltd.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a cautious outlook for investors amid mixed signals.

Pfizer Ltd. is currently rated Sell by MarketsMOJO, a rating that was last updated on 29 December 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the stock’s current position as of 19 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a bearish stance. This transition is underscored by deteriorating technical indicators including MACD, Bollinger Bands, and moving averages, signalling increased selling pressure despite some bullish volume trends. Investors should carefully analyse these developments as the stock navigates a challenging market environment.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical indicators suggest a cautious outlook for investors navigating this evolving landscape.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating technical parameters, suggests increased selling pressure and a cautious outlook for investors.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters suggest a nuanced outlook for investors navigating this evolving landscape.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of the company's performance and outlook.

Pfizer Ltd. has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a strong one-year return outperforming the Sensex, recent price action and technical parameters suggest caution for investors as the stock faces downward pressure in the near term.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. witnessed a sharp gap down at the opening bell on 2 Mar 2026, declining by 5.11% to an intraday low of Rs 4,809.3, reflecting heightened market concerns and a continuation of recent downward momentum. The stock underperformed its sector and the broader market, marking a weak start to the trading session.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. demonstrated a strong intraday performance on 10 Feb 2026, surging to an intraday high of Rs 5,150, marking an 8.18% increase from its previous close. The pharmaceutical giant outpaced the broader market and its sector peers, reflecting heightened trading activity and volatility throughout the session.

Pfizer Ltd., one of India's leading pharmaceutical companies with a market capitalisation of ₹21,203 crores, reported mixed results for Q2 FY26 (Jul-Sep'25), with net profit declining 1.42% quarter-on-quarter to ₹189.02 crores despite revenue growth of 6.52%. The stock rallied 3.93% on February 9, 2026, trading at ₹4,775, though it remains down 20.25% from its 52-week high of ₹5,987.65, reflecting investor concerns about premium valuations and decelerating growth momentum.